ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Azacitidine

Also written as “azacitidine”, “Azacitidine (AZA)” and “Eganelisib in combination with azacitidine”.

Its studies are mostly in Leukemia, Myeloid, Acute · Myelodysplastic Syndromes · Carcinoma, Non-Small-Cell Lung · Hematologic Neoplasms · Lymphoma, T-Cell, led by 9 companies.

Drug pageAzacitidine: every studyMany companies study it; this page follows only the 27 they lead. All 441 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 13, 201027 company-led studies, 3 open or runningNext primary completion: Jul 13, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb161 open or runningphase 4since Sep 13, 2010Oct 31, 2003none ahead
Takedaits history only30 open or runningphase 3since Aug 30, 2017May 28, 2009none ahead
Hikma Pharmaceuticalsits history only21 open or runningphase 1since Mar 11, 2024Mar 11, 2024none ahead
Bioniche Pharma USAits history only10 open or runningphase 1since Jun 25, 2010Jun 25, 2010none ahead
Johnson & Johnsonits history only10 open or runningphase 2since Feb 7, 2020Feb 7, 2020none ahead
Merckits history only10 open or runningphase 2since Nov 24, 2014Nov 24, 2014none ahead
Nanexa ABits history only10 open or runningphase 1since May 11, 2021May 11, 2021none ahead
Nob Hill Therapeuticsits history only11 open or runningphase 2since Sep 10, 2026Sep 10, 2026Jul 13, 2029phase 2 · NCT07864584
Sarah Cannon Research Instituteits history only10 open or runningphase 2since Oct 4, 2006Oct 4, 2006none ahead

Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical, Hoffmann-La Roche, Roche-Genentech, Takeda Development Center Americas and argenx.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Oct 31, 2003.

  1. Sep 11, 2007Phase 1 study in Myelodysplastic SyndromesNCT00528983 · 133 enrolled · United States
  2. Apr 1, 2008Phase 1 study in Multiple MyelomaNCT00652626 · 31 enrolled · United States
  3. Apr 23, 2008Phase 2 study in Leukemia, Myeloid, AcuteNCT00666497 · 6 enrolled · United States, Canada, United Kingdom
  4. Sep 25, 2008Phase 1 study in Leukemia, Myeloid, AcuteNCT00761722 · 31 enrolled · United States
  5. Feb 16, 2010Phase 3 study in Leukemia, Myeloid, AcuteNCT01074047 · 488 enrolled · United States, Australia, Austria and more
  6. Aug 20, 2010Phase 3 study in Myelodysplastic SyndromesNCT01186939 · 40 enrolled · Australia, Bulgaria, France and more
  7. Sep 13, 2010Phase 4 study in Myelodysplastic SyndromesNCT01201811 · 44 enrolled · Taiwan
  8. May 19, 2011Phase 2 study in Leukemia, Myeloid, AcuteNCT01358734 · 88 enrolled · United States, Canada
  9. May 14, 2012Phase 2 study in Myelodysplastic SyndromesNCT01599325 · 72 enrolled · China
  10. Apr 14, 2015Phase 2 study in Myelodysplastic SyndromesNCT02447666 · 28 enrolled · Austria, Belgium, Czechia and more
  11. May 19, 2015Phase 2 study in Leukemia, Myeloid, AcuteNCT02450877 · 7 enrolled · Denmark, Germany, Netherlands
  12. Feb 5, 2016Phase 2 study in Leukemia, Myeloid, AcuteNCT02677922 · 130 enrolled · United States, Australia, Belgium and more
  13. Oct 9, 2018Phase 3 study in Lymphoma, T-CellNCT03703375 · 93 enrolled · Japan
  14. Feb 2, 2021Phase 1 study in Leukemia, MyeloidNCT04748848 · 1 enrolled · United States, Belgium, France and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 16 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04748848Leukemia, Myeloid · United States, Belgium, France and more1TerminatedMar 9, 20221
NCT03703375Lymphoma, T-Cell · Japan3CompletedFeb 10, 202193
NCT02677922Leukemia, Myeloid, Acute · United States, Australia, Belgium and more2Active, not recruitingAug 2, 2018130
NCT02450877Leukemia, Myeloid, Acute · Denmark, Germany, Netherlands2CompletedOct 10, 20187
NCT02447666Myelodysplastic Syndromes · Austria, Belgium, Czechia and more2CompletedFeb 28, 201828
NCT01599325Myelodysplastic Syndromes · China2CompletedJan 29, 201572
NCT01358734Leukemia, Myeloid, Acute · United States, Canada2CompletedMay 19, 201588
NCT01201811Myelodysplastic Syndromes · Taiwan4CompletedMay 1, 201344
NCT01186939Myelodysplastic Syndromes · Australia, Bulgaria, France and more3CompletedSep 1, 200940
NCT01074047Leukemia, Myeloid, Acute · United States, Australia, Austria and more3CompletedJan 22, 2014488
NCT00761722Leukemia, Myeloid, Acute · United States1CompletedApr 6, 201631
NCT00666497Leukemia, Myeloid, Acute · United States, Canada, United Kingdom2TerminatedApr 20096
NCT00652626Multiple Myeloma · United States1CompletedJul 1, 201231
NCT00528983Myelodysplastic Syndromes · United States1CompletedJul 31, 2013133
NCT00102687Myelodysplastic Syndromes · United States2CompletedAug 1, 2008151
NCT00071799Myelodysplastic Syndromes · United States, Australia, Bulgaria and more3CompletedJul 1, 2007358

How it is read

Names in the registry

  • “Azacitidine”, 36 entries
  • “azacitidine”, 8 entries
  • “Azacitidine (AZA)”, 2 entries
  • “Eganelisib in combination with azacitidine”, 1 entry
  • “NHT102”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.